Assenagon Asset Management S.A. Sells 90,551 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Assenagon Asset Management reduced its Medpace stake by 77.8% in the second quarter, selling 90,551 shares and retaining 25,772 shares valued at approximately $13.65 million. Institutional investors collectively own 77.98% of Medpace.
• Medpace exceeded quarterly expectations, reporting $4.25 in EPS on $707.33 million in revenue, with revenue rising 17.2% year over year. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
• Medpace shares opened at $602.43, while analysts maintain a consensus “Hold” rating and an average price target of $584.18; insiders have also sold more than 31,000 shares worth $16.2 million over the past 90 days.

Assenagon Asset Management S.A. cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 77.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 25,772 shares of the company's stock after selling 90,551 shares during the period. Assenagon Asset Management S.A. owned 0.09% of Medpace worth $13,649,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace during the 4th quarter valued at about $30,000. Elyxium Wealth LLC bought a new position in Medpace in the fourth quarter worth about $30,000. Basecamp Wealth Advisors LLC raised its stake in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company's stock worth $33,000 after buying an additional 45 shares in the last quarter. Quarry LP purchased a new stake in Medpace in the third quarter worth about $35,000. Finally, Bayban purchased a new stake in Medpace in the fourth quarter worth about $44,000. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

MEDP opened at $602.43 on Tuesday. The stock has a 50-day moving average price of $525.16 and a 200-day moving average price of $491.95. The firm has a market cap of $16.81 billion, a PE ratio of 35.31, a P/E/G ratio of 2.63 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace's revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wall Street Zen downgraded Medpace from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Weiss Ratings restated a "hold (c+)" rating on shares of Medpace in a research note on Thursday, July 2nd. TD Cowen upped their price target on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research note on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and increased their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Truist Financial raised their price objective on Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $584.18.

Insider Transactions at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company's stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 3,728 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $600.85, for a total value of $2,239,968.80. Following the sale, the chief executive officer directly owned 642,456 shares in the company, valued at $386,019,687.60. This trade represents a 0.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 31,087 shares of company stock worth $16,203,054. Corporate insiders own 20.50% of the company's stock.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source